Novavax’s Protein-Based COVID-19 Vaccine Receives FDA Authorization

By Jessica Karins / August 30, 2024 at 4:23 PM

FDA has granted emergency use authorization an updated Novavax protein-based COVID-19 vaccine that aims to more closely target circulating variants of the virus than the company’s previous version, the agency announced Friday (Aug. 30).


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.